NASDAQ:SIBN

SI-BONE Competitors

$33.16
+0.19 (+0.58 %)
(As of 04/14/2021 12:46 PM ET)
Add
Compare
Today's Range
$32.81
Now: $33.16
$33.74
50-Day Range
$28.94
MA: $31.57
$34.02
52-Week Range
$12.05
Now: $33.16
$35.68
Volume2,892 shs
Average Volume307,526 shs
Market Capitalization$1.09 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.41

Competitors

SI-BONE (NASDAQ:SIBN) Vs. GKOS, CMD, NUVA, MMSI, ATRC, and IRTC

Should you be buying SIBN stock or one of its competitors? Companies in the industry of "surgical & medical instruments" are considered alternatives and competitors to SI-BONE, including Glaukos (GKOS), Cantel Medical (CMD), NuVasive (NUVA), Merit Medical Systems (MMSI), AtriCure (ATRC), and iRhythm Technologies (IRTC).

Glaukos (NYSE:GKOS) and SI-BONE (NASDAQ:SIBN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, valuation, risk, dividends and analyst recommendations.

Profitability

This table compares Glaukos and SI-BONE's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Glaukos-33.61%-7.99%-5.87%
SI-BONE-61.67%-45.03%-29.29%

Institutional and Insider Ownership

65.3% of SI-BONE shares are owned by institutional investors. 8.7% of Glaukos shares are owned by company insiders. Comparatively, 15.5% of SI-BONE shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk and Volatility

Glaukos has a beta of 1.87, meaning that its stock price is 87% more volatile than the S&P 500. Comparatively, SI-BONE has a beta of 1.41, meaning that its stock price is 41% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations for Glaukos and SI-BONE, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Glaukos16102.00
SI-BONE00503.00

Glaukos presently has a consensus price target of $66.3750, indicating a potential downside of 21.44%. SI-BONE has a consensus price target of $32.60, indicating a potential downside of 1.54%. Given SI-BONE's stronger consensus rating and higher probable upside, analysts clearly believe SI-BONE is more favorable than Glaukos.

Earnings & Valuation

This table compares Glaukos and SI-BONE's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Glaukos$236.98 million16.40$15.42 million($0.10)-848.80
SI-BONE$67.30 million16.13$-38,400,000.00($1.55)-21.39

Glaukos has higher revenue and earnings than SI-BONE. Glaukos is trading at a lower price-to-earnings ratio than SI-BONE, indicating that it is currently the more affordable of the two stocks.

Summary

Glaukos beats SI-BONE on 8 of the 14 factors compared between the two stocks.

SI-BONE (NASDAQ:SIBN) and Cantel Medical (NYSE:CMD) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Insider & Institutional Ownership

65.3% of SI-BONE shares are owned by institutional investors. Comparatively, 95.0% of Cantel Medical shares are owned by institutional investors. 15.5% of SI-BONE shares are owned by company insiders. Comparatively, 10.7% of Cantel Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and recommmendations for SI-BONE and Cantel Medical, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
SI-BONE00503.00
Cantel Medical12102.00

SI-BONE presently has a consensus price target of $32.60, suggesting a potential downside of 1.54%. Cantel Medical has a consensus price target of $71.50, suggesting a potential downside of 16.22%. Given SI-BONE's stronger consensus rating and higher probable upside, equities research analysts clearly believe SI-BONE is more favorable than Cantel Medical.

Volatility & Risk

SI-BONE has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500. Comparatively, Cantel Medical has a beta of 1.54, meaning that its share price is 54% more volatile than the S&P 500.

Profitability

This table compares SI-BONE and Cantel Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SI-BONE-61.67%-45.03%-29.29%
Cantel Medical3.38%11.19%4.10%

Valuation & Earnings

This table compares SI-BONE and Cantel Medical's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SI-BONE$67.30 million16.13$-38,400,000.00($1.55)-21.39
Cantel Medical$1.02 billion3.55$13.71 million$1.6551.75

Cantel Medical has higher revenue and earnings than SI-BONE. SI-BONE is trading at a lower price-to-earnings ratio than Cantel Medical, indicating that it is currently the more affordable of the two stocks.

Summary

Cantel Medical beats SI-BONE on 9 of the 14 factors compared between the two stocks.

SI-BONE (NASDAQ:SIBN) and NuVasive (NASDAQ:NUVA) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, profitability, valuation, dividends and risk.

Insider & Institutional Ownership

65.3% of SI-BONE shares are held by institutional investors. 15.5% of SI-BONE shares are held by company insiders. Comparatively, 0.9% of NuVasive shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares SI-BONE and NuVasive's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SI-BONE$67.30 million16.13$-38,400,000.00($1.55)-21.39
NuVasive$1.17 billion3.03$65.23 million$2.4727.91

NuVasive has higher revenue and earnings than SI-BONE. SI-BONE is trading at a lower price-to-earnings ratio than NuVasive, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

SI-BONE has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500. Comparatively, NuVasive has a beta of 1.36, indicating that its share price is 36% more volatile than the S&P 500.

Profitability

This table compares SI-BONE and NuVasive's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SI-BONE-61.67%-45.03%-29.29%
NuVasive-0.84%8.00%3.06%

Analyst Recommendations

This is a summary of current ratings and target prices for SI-BONE and NuVasive, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
SI-BONE00503.00
NuVasive27702.31

SI-BONE currently has a consensus target price of $32.60, suggesting a potential downside of 1.54%. NuVasive has a consensus target price of $64.8667, suggesting a potential downside of 5.70%. Given SI-BONE's stronger consensus rating and higher possible upside, research analysts clearly believe SI-BONE is more favorable than NuVasive.

SI-BONE (NASDAQ:SIBN) and Merit Medical Systems (NASDAQ:MMSI) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.

Institutional and Insider Ownership

65.3% of SI-BONE shares are owned by institutional investors. Comparatively, 99.5% of Merit Medical Systems shares are owned by institutional investors. 15.5% of SI-BONE shares are owned by company insiders. Comparatively, 4.7% of Merit Medical Systems shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares SI-BONE and Merit Medical Systems' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SI-BONE$67.30 million16.13$-38,400,000.00($1.55)-21.39
Merit Medical Systems$994.85 million3.47$5.45 million$1.4642.40

Merit Medical Systems has higher revenue and earnings than SI-BONE. SI-BONE is trading at a lower price-to-earnings ratio than Merit Medical Systems, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

SI-BONE has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500. Comparatively, Merit Medical Systems has a beta of 1.21, meaning that its share price is 21% more volatile than the S&P 500.

Profitability

This table compares SI-BONE and Merit Medical Systems' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SI-BONE-61.67%-45.03%-29.29%
Merit Medical Systems-3.05%9.02%4.91%

Analyst Recommendations

This is a summary of current ratings and recommmendations for SI-BONE and Merit Medical Systems, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
SI-BONE00503.00
Merit Medical Systems01702.88

SI-BONE presently has a consensus target price of $32.60, suggesting a potential downside of 1.54%. Merit Medical Systems has a consensus target price of $64.3750, suggesting a potential upside of 4.27%. Given Merit Medical Systems' higher possible upside, analysts clearly believe Merit Medical Systems is more favorable than SI-BONE.

Summary

Merit Medical Systems beats SI-BONE on 9 of the 14 factors compared between the two stocks.

SI-BONE (NASDAQ:SIBN) and AtriCure (NASDAQ:ATRC) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.

Institutional and Insider Ownership

65.3% of SI-BONE shares are owned by institutional investors. Comparatively, 94.7% of AtriCure shares are owned by institutional investors. 15.5% of SI-BONE shares are owned by company insiders. Comparatively, 5.8% of AtriCure shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and recommmendations for SI-BONE and AtriCure, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
SI-BONE00503.00
AtriCure00703.00

SI-BONE presently has a consensus target price of $32.60, suggesting a potential downside of 1.54%. AtriCure has a consensus target price of $67.1429, suggesting a potential upside of 0.83%. Given AtriCure's higher possible upside, analysts clearly believe AtriCure is more favorable than SI-BONE.

Earnings and Valuation

This table compares SI-BONE and AtriCure's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SI-BONE$67.30 million16.13$-38,400,000.00($1.55)-21.39
AtriCure$230.81 million13.15$-35,190,000.00($1.07)-62.24

AtriCure has higher revenue and earnings than SI-BONE. AtriCure is trading at a lower price-to-earnings ratio than SI-BONE, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

SI-BONE has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500. Comparatively, AtriCure has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500.

Profitability

This table compares SI-BONE and AtriCure's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SI-BONE-61.67%-45.03%-29.29%
AtriCure-21.74%-14.83%-7.77%

Summary

AtriCure beats SI-BONE on 9 of the 13 factors compared between the two stocks.

iRhythm Technologies (NASDAQ:IRTC) and SI-BONE (NASDAQ:SIBN) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, valuation, profitability, analyst recommendations, earnings and dividends.

Profitability

This table compares iRhythm Technologies and SI-BONE's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
iRhythm Technologies-20.97%-28.89%-15.11%
SI-BONE-61.67%-45.03%-29.29%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for iRhythm Technologies and SI-BONE, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
iRhythm Technologies07502.42
SI-BONE00503.00

iRhythm Technologies currently has a consensus target price of $171.7692, indicating a potential upside of 88.45%. SI-BONE has a consensus target price of $32.60, indicating a potential downside of 1.54%. Given iRhythm Technologies' higher probable upside, equities research analysts clearly believe iRhythm Technologies is more favorable than SI-BONE.

Earnings and Valuation

This table compares iRhythm Technologies and SI-BONE's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
iRhythm Technologies$214.55 million12.41$-54,570,000.00($2.16)-42.25
SI-BONE$67.30 million16.13$-38,400,000.00($1.55)-21.39

SI-BONE has lower revenue, but higher earnings than iRhythm Technologies. iRhythm Technologies is trading at a lower price-to-earnings ratio than SI-BONE, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

iRhythm Technologies has a beta of 1.68, meaning that its share price is 68% more volatile than the S&P 500. Comparatively, SI-BONE has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500.

Insider & Institutional Ownership

65.3% of SI-BONE shares are held by institutional investors. 3.1% of iRhythm Technologies shares are held by company insiders. Comparatively, 15.5% of SI-BONE shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

SI-BONE beats iRhythm Technologies on 7 of the 13 factors compared between the two stocks.


SI-BONE Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Glaukos logo
GKOS
Glaukos
0.9$84.88+2.3%$3.80 billion$236.98 million-51.44Analyst Upgrade
Analyst Revision
Cantel Medical logo
CMD
Cantel Medical
1.3$85.38+0.5%$3.59 billion$1.02 billion101.64
NuVasive logo
NUVA
NuVasive
1.1$68.93+0.6%$3.52 billion$1.17 billion-313.32
Merit Medical Systems logo
MMSI
Merit Medical Systems
1.5$61.90+1.5%$3.39 billion$994.85 million-116.79
AtriCure logo
ATRC
AtriCure
1.5$66.60+1.0%$3.01 billion$230.81 million-57.91Analyst Report
iRhythm Technologies logo
IRTC
iRhythm Technologies
1.5$91.27+6.1%$2.50 billion$214.55 million-47.79Analyst Report
Unusual Options Activity
Analyst Revision
News Coverage
Axonics Modulation Technologies logo
AXNX
Axonics Modulation Technologies
1.3$59.45+1.6%$2.43 billion$13.82 million-30.33
Inovio Pharmaceuticals logo
INO
Inovio Pharmaceuticals
1.4$9.10+4.1%$1.82 billion$4.11 million-6.69
GenMark Diagnostics logo
GNMK
GenMark Diagnostics
1.5$23.99+0.0%$1.75 billion$88.02 million-58.51Increase in Short Interest
Luminex logo
LMNX
Luminex
1.5$36.86+0.2%$1.75 billion$334.64 million94.52Analyst Upgrade
Unusual Options Activity
News Coverage
Silk Road Medical logo
SILK
Silk Road Medical
1.1$51.32+2.6%$1.72 billion$63.35 million-42.07
Alphatec logo
ATEC
Alphatec
0.8$17.20+0.4%$1.63 billion$113.43 million-15.64Insider Selling
Pulmonx logo
LUNG
Pulmonx
1.4$43.90+2.5%$1.61 billion$32.60 million0.00Increase in Short Interest
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.7$37.69+3.1%$1.47 billion$236.54 million-57.11
MiMedx Group logo
MDXG
MiMedx Group
1.7$12.22+1.5%$1.38 billion$299.26 million-13.00
Atrion logo
ATRI
Atrion
1.1$648.60+0.5%$1.18 billion$155.07 million36.54
Tactile Systems Technology logo
TCMD
Tactile Systems Technology
1.2$56.40+2.0%$1.08 billion$189.49 million-125.33
Cerus logo
CERS
Cerus
1.5$6.34+1.3%$1.05 billion$74.65 million-16.26News Coverage
LeMaitre Vascular logo
LMAT
LeMaitre Vascular
1.9$49.69+0.6%$1.03 billion$117.23 million53.43
OrthoPediatrics logo
KIDS
OrthoPediatrics
1.5$49.60+1.1%$964.42 million$72.55 million-34.44
AngioDynamics logo
ANGO
AngioDynamics
1.4$24.00+0.1%$916.43 million$264.16 million-5.37Decrease in Short Interest
CryoLife logo
CRY
CryoLife
1.8$22.70+0.4%$891.15 million$276.22 million-59.74
Orthofix Medical logo
OFIX
Orthofix Medical
1.2$43.12+0.8%$847.99 million$459.95 million35.93
Surmodics logo
SRDX
Surmodics
1.3$56.96+0.9%$790.83 million$94.86 million712.00
OraSure Technologies logo
OSUR
OraSure Technologies
1.7$10.30+0.2%$742.48 million$154.60 million-44.78
Antares Pharma logo
ATRS
Antares Pharma
1.8$4.03+0.2%$679.37 million$123.86 million67.18
Intersect ENT logo
XENT
Intersect ENT
1.4$19.94+1.0%$652.07 million$109.14 million-10.44
Vapotherm logo
VAPO
Vapotherm
1.5$23.03+0.2%$595.63 million$48.10 million-10.97
SeaSpine logo
SPNE
SeaSpine
1.3$21.55+2.0%$589.95 million$159.08 million-12.90Analyst Upgrade
Anika Therapeutics logo
ANIK
Anika Therapeutics
1.5$41.06+1.6%$579.22 million$114.51 million-87.36Gap Down
Pulse Biosciences logo
PLSE
Pulse Biosciences
1.5$21.98+2.9%$556.70 millionN/A-9.68
Accuray logo
ARAY
Accuray
2.3$5.26+0.8%$484.93 million$382.93 million37.57News Coverage
iCAD logo
ICAD
iCAD
1.5$18.46+2.0%$451.02 million$31.34 million-19.43
AVITA Medical logo
RCEL
AVITA Medical
1.5$20.88+0.6%$449.02 million$14.26 million-10.09Analyst Report
Increase in Short Interest
ClearPoint Neuro logo
CLPT
ClearPoint Neuro
1.4$20.91+3.8%$415.73 million$11.22 million-47.52News Coverage
Profound Medical logo
PROF
Profound Medical
1.6$20.20+1.2%$414.73 million$4.17 million-17.26News Coverage
Cytosorbents logo
CTSO
Cytosorbents
1.7$9.05+2.2%$400.19 million$24.95 million-27.42
PAVmed logo
PAVM
PAVmed
1.4$4.97+4.2%$392.51 millionN/A-6.54Gap Down
UFP Technologies logo
UFPT
UFP Technologies
1.3$49.50+0.4%$370.59 million$198.38 million24.75
Acutus Medical logo
AFIB
Acutus Medical
1.3$13.29+0.9%$370.01 million$2.84 million0.00News Coverage
Soliton logo
SOLY
Soliton
1.1$17.45+4.7%$352.56 millionN/A-23.27
Neuronetics logo
STIM
Neuronetics
1.5$13.15+3.3%$322.94 million$62.66 million-7.83
Apyx Medical logo
APYX
Apyx Medical
1.0$9.51+1.4%$321.90 million$28.15 million-20.23Gap Down
Utah Medical Products logo
UTMD
Utah Medical Products
0.9$88.57+1.5%$317.93 million$46.90 million27.94
IRadimed logo
IRMD
IRadimed
1.5$23.94+2.2%$301.25 million$38.52 million74.81News Coverage
Gap Up
DarioHealth logo
DRIO
DarioHealth
1.3$18.59+0.1%$285.89 million$7.56 million-2.32
Co-Diagnostics logo
CODX
Co-Diagnostics
1.6$9.75+2.2%$273.47 million$220,000.0012.04
T2 Biosystems logo
TTOO
T2 Biosystems
1.4$1.40+1.4%$204.92 million$8.34 million-2.03
TELA Bio logo
TELA
TELA Bio
2.1$13.90+2.2%$200.72 million$15.45 million-4.78
Titan Medical logo
TMDI
Titan Medical
1.2$1.73+1.7%$186.19 millionN/A173.00Analyst Report
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.